Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 3/2013

01-07-2013 | Case Report

Ductal carcinoma in situ with isolated tumor cells in the sentinel lymph node in a 17-year-old adolescent girl

Authors: Tomoi Sato, Ichiro Muto, Masaki Hasegawa, Takashi Aono, Takeshi Sakai, Takeshi Oya

Published in: Breast Cancer | Issue 3/2013

Login to get access

Abstract

We report here a quite rare case of ductal carcinoma in situ (DCIS) with isolated tumor cells in the sentinel lymph node in a 17-year-old adolescent girl whose mother also had advanced breast cancer. Findings included an elastic mass in the right breast accompanied by serous nipple discharge. DCIS of the breast was diagnosed following core needle biopsy. Although no invasive focus was clearly observed in the mastectomy sample, isolated tumor cells were found in the sentinel lymph node. Although the family refused genetic testing, a hereditary abnormality may have played a role in the carcinogenesis in this case.
Literature
1.
2.
The Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer 2005;Suppl 12.
3.
Rosen PP. Intraductal carcinoma. In: Rosen PP, editor. Rosen’s breast pathology. Philadelphia: Lippincott-Raven; 1996. p. 227–73.
4.
Sobin LH, Wittekind CH, editors. TNM classification of malignant tumors. 6th ed. New York: Wiley; 2002. p. 9–13.
5.
Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BD, editors. SEER cancer statistics review, 1975–2006. Bethesda: National Cancer Institute; 2009. http://​seer.​cancer.​gov/​csr/​1975_​2006/​, based on November 2008 SEER data submission. Accessed 24 Nov 2009.
6.
Rogers DA, Lobe TE, Rao BN, Fleming ID, Schropp KP. Breast malignancy in children. J Pediatr Surg. 1994;29:48–51.CrossRefPubMed
7.
Murphy JJ, Morzaria S, Gow KW, Magee JF. Breast cancer in a 6-year-old child. J Pediatr Surg. 2000;35:765–7.CrossRefPubMed
8.
Corroppolo M, Erculiani E, Zampieri N, Gobbato M, Camoglio FS, Giacomello L. Ductal carcinoma in situ in a 15-year-old boy with gynecomastia: a case report. Pediatr Surg Int. 2008;24:943–5.CrossRefPubMed
9.
Tea MK, Asseryanis E, Kroiss R, Kubista E, Wagner T. Surgical breast lesions in adolescent females. Pediatr Surg Int. 2009;25:73–5.CrossRefPubMed
10.
Arai M, Utsunomiya J, Miki Y. Familial breast and ovarian cancers. Int J Clin Oncol. 2004;9:270–82.CrossRefPubMed
11.
Youngson BJ, Cranor M, Rosen PP. Epithelial displacement in surgical breast specimens following needling procedures. Am J Surg Pathol. 1994;18:898–903.CrossRef
12.
Bleiweiss IJ, Nagi CS, Jaffer S. Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma. J Clin Oncol. 2006;24:2013–8.CrossRefPubMed
13.
van Rijk MC, Peterse JL, Nieweg OE, Oldenburg HA, Rutgers EJ, Kroon BB. Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submictometastases in sentinel lymph nodes. Cancer. 2006;107:467–71.CrossRefPubMed
14.
Reed J, Rosman M, Verbanac KM, Mannie A, Cheng Z, Tafra L. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the Prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study. J Am Coll Surg. 2009;208:333–40.CrossRefPubMed
15.
McCready DR, Yong WS, Ng AKT, Miller N, Done S, Youngson B. Influence of the new AJCC breast cancer staging system on sentinel lymph node positivity and false-negative rates. J Natl Cancer Inst. 2004;96:873–5.CrossRefPubMed
16.
Turner RR, Chu KU, Qi K, Botnick LE, Hansen NM, Glass EC, Giuliano AE. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer. 2000;89:574–81.CrossRefPubMed
17.
Kamath VJ, Giuliano R, Dauway EL, Cantor A, Berman C, Ku NN, et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg. 2001;136:688–92.CrossRefPubMed
18.
19.
Serour F, Gilad A, Kopolovic J, Krispin M. Secretory breast cancer in childhood and adolescence: report of a case and review of the literature. Med Padiatr Oncol. 1992;20:341–4.CrossRef
20.
Herz H, Cooke B, Goldstein D. Metastatic secretory breast cancer. Non-responsiveness to chemotherapy: case report and review of the literature. Ann Oncol. 2000;11:1343–7.CrossRefPubMed
21.
Walker RA, Lees E, Webb MB, Dearing SJ. Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer. 1996;74:1796–800.CrossRefPubMed
22.
Maggard MA, O’Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY. Do young breast cancer patients have worse outcome? J Surg Res. 2003;113:109–13.CrossRefPubMed
23.
National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst Monogr. 2001;30:5–15.CrossRef
24.
Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133–44.CrossRefPubMed
25.
Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ, et al. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20:1319–29.CrossRefPubMed
Metadata
Title
Ductal carcinoma in situ with isolated tumor cells in the sentinel lymph node in a 17-year-old adolescent girl
Authors
Tomoi Sato
Ichiro Muto
Masaki Hasegawa
Takashi Aono
Takeshi Sakai
Takeshi Oya
Publication date
01-07-2013
Publisher
Springer Japan
Published in
Breast Cancer / Issue 3/2013
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-010-0205-x

Other articles of this Issue 3/2013

Breast Cancer 3/2013 Go to the issue

Review Article

Animal model for mammary tumor growth in the bone microenvironment

Case Report

Phyllodes tumor showing intraductal growth

Letter to the Editor

Measuring of the maximum fat lesion ratio

Original Article

Identification of candidates for postmastectomy radiotherapy in patients with pT3N0M0 breast cancer

Original Article

Impact of aggregate of risk factors for isolated locoregional failure in breast cancer patients treated with mastectomy without radiotherapy

Author’s reply

Reply to Ozkan et al.: a role of elastography using maximum fat-to-lesion ratio for the diagnosis of breast lesions
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits